Treatment Clinical Trials for Gastrointestinal Neuroendocrine Tumor G1
Clinical trials are research studies that involve people. The clinical trials on this list are for gastrointestinal neuroendocrine tumor g1 treatment. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Testing Cabozantinib in Patients with Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Location: 372 locations
Peptide Receptor Radionuclide Therapy before and after Surgery for the Treatment of Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumor
This phase I trial learns about the feasibility and safety of using peptide receptor radionuclide therapy (PRRT) in treating patients with World Health Organization (WHO) grade 1 or 2, SSTR positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have spread to other parts of the body (metastatic). PRRT treatment is based on the administration of a radioactive product, 177Lu dotatate, and its use before and after surgery is thought to increase the overall survival benefit for patients with GEP-NETs.
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California